Why Hims & Hers Health, Inc. (HIMS) stock moved
Hims & Hers Health, Inc. (HIMS) shares climbed 6.5% to $31.59 as of August 8, 2026, a significant gain from the prior close of $29.66. BestStocks flagged the session as a major change for HIMS. The move is tied to price move up. Below, we break down what changed for HIMS, why it matters for investors, how the stock reacted, and the catalysts on the calendar.
HIMS climbed 6.5% to $31.59
HIMS climbed 6.5% in its latest session, moving from $29.66 to $31.59.
What it means for Hims & Hers Health, Inc. investors
For Hims & Hers Health, Inc. investors, the recent signals are mixed, leaving the near-term picture neutral / mixed. On the constructive side: Material positive event; Strong 6.5% price move on light volume. Weighing against that: Hims & Hers Health, Inc. (HIMS) moved -9.39% from $37.17 to $33.68 on 2026-07-16; Hims & Hers Health, Inc. moved -9.04% intraday from $38.28 to $34.82. Wall Street's consensus price target sits at $26.91, implying -14.8% downside from $31.59. BestStocks rates the overall signal quality low (53/100). With earnings roughly 2 days out, the next report is the most likely near-term test of the move.
HIMS price reaction
HIMS last traded at $31.59, up $1.93 (+6.51%) from the previous close of $29.66. The session traded on 0.4× average volume (below avg), so participation was unremarkable. Over the past month the stock has ranged between $25.00 and $37.17, and it currently sits about 54% of the way up that band.
Bullish and bearish analyst opinions on Hims & Hers Health, Inc. (HIMS)
The consensus analyst price target on Hims & Hers Health, Inc. (HIMS) is $26.91, 14.8% below the recent $31.59. Over the past 90 days analysts logged 0 upgrades, 14 maintains, and 0 downgrades. Here is how the bullish and bearish cases on HIMS line up.
The bullish case
- The Street's most bullish target is $40.00 (+26.6%).
- Material positive event.
- Strong 6.5% price move on light volume.
- Hims & Hers Health, Inc. (HIMS) moved +5.75% from $35.15 to $37.17 on 2026-07-15.
- Positive price momentum.
The bearish case
- The consensus analyst price target of $26.91 sits 14.8% below the recent $31.59, so the average target sees limited room to run.
- The most bearish analyst target is $12.50 (-60.4%).
- Hims & Hers Health, Inc. (HIMS) moved -9.39% from $37.17 to $33.68 on 2026-07-16.
- HIMS declined 3.39% to $36.27 in early trading despite a Canaccord analyst target price increase ahead of an FDA review announced on July 1.
Weighing both sides, BestStocks' composite read of recent signals is roughly balanced, as the bull-versus-bear meter above shows. This is an educational summary of the bull and bear case, not investment advice.
Analyst price targets and ratings are FMP consensus figures as of Aug 7, 2026; other aggregators may differ. High and low targets show the range of estimates, not forecasts.
Previous notable changes for HIMS
In-depth HIMS event analyses
Frequently asked questions about HIMS
Why did Hims & Hers Health, Inc. (HIMS) stock move?
HIMS climbed 6.5% to $31.59. No single company-specific catalyst was confirmed during the move window, and it looks technical.
How much did HIMS stock rise?
HIMS gained 6.51% ($1.93) versus the prior close of $29.66, last trading at $31.59 on 0.4× average volume.
When is Hims & Hers Health, Inc.'s next earnings date?
HIMS's next earnings report is estimated for 2026-08-10 — about 2 days away.
What is the analyst price target for HIMS?
The consensus analyst price target for HIMS is $26.91, about 14.8% below the current $31.59. Over the past 90 days, analysts recorded 0 upgrades, 14 maintains, and 0 downgrades.
How BestStocks tracks HIMS
This page is generated automatically by BestStocks' change-detection system after price move up was detected and verified against independent data sources. It draws on 20 tracked change events for HIMS, cross-checked against the data sources listed below. Price, volume, and market-capitalization figures are the live intraday quote as of August 8, 2026 and refresh as new information is detected; for companies with multiple share classes, market-cap figures can differ by data source. Analyst price targets and ratings are FMP consensus. This is an educational summary of what changed and why — not personalized investment advice.